{"id":"NCT03635983","sponsor":"Bristol-Myers Squibb","briefTitle":"A Study of NKTR-214 Combined With Nivolumab vs Nivolumab Alone in Participants With Previously Untreated Inoperable or Metastatic Melanoma","officialTitle":"A Phase 3, Randomized, Open-label Study of NKTR-214 Combined With Nivolumab Versus Nivolumab in Participants With Previously Untreated Unresectable or Metastatic Melanoma","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-09-21","primaryCompletion":"2021-11-19","completion":"2024-03-19","firstPosted":"2018-08-17","resultsPosted":"2022-12-19","lastUpdate":"2025-04-01"},"enrollment":783,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Melanoma"],"interventions":[{"type":"BIOLOGICAL","name":"NKTR-214","otherNames":["Bempegaldesleukin","BMS-986321"]},{"type":"BIOLOGICAL","name":"Nivolumab","otherNames":["Opdivo","BMS-936558"]}],"arms":[{"label":"Combination","type":"EXPERIMENTAL"},{"label":"Monotherapy","type":"EXPERIMENTAL"}],"summary":"The purpose of the study is to test the effectiveness (how well the drug works), safety, and tolerability of the investigational drug called NKTR-214, when combined with nivolumab versus nivolumab given alone in participants with previously untreated melanoma skin cancer that is either unable to be surgically removed or has spread","primaryOutcome":{"measure":"Objective Response Rate (ORR) Per Blinded Independent Central Review (BICR)","timeFrame":"From date of randomization to disease progression (Up to 37 months)","effectByArm":[{"arm":"Bempegaldesleukin + Nivolumab","deltaMin":27.7,"sd":null},{"arm":"Nivolumab","deltaMin":36,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0311"}]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":3},"locations":{"siteCount":167,"countries":["United States","Argentina","Australia","Austria","Belgium","Brazil","Canada","Chile","Czechia","Finland","France","Germany","Greece","Ireland","Israel","Italy","Mexico","Netherlands","New Zealand","Poland","Portugal","Romania","Russia","Spain","Sweden","Switzerland","United Kingdom"]},"refs":{"pmids":["37651676","32723187"],"seeAlso":["https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html","https://www.BMSClinicalTrials.com"]},"adverseEventsSummary":{"seriousAny":{"events":161,"n":388},"commonTop":["Fatigue","Pruritus","Pyrexia","Nausea","Diarrhoea"]}}